Repligen Corporation Earnings Recaps
Q1 2026
May 6, 2026
The stock rose 6.4% following better-than-expected revenue growth, margin expansion, and an improved full-year adjusted EPS outlook supported by strong demand across segments and accelerated strategic initiatives.
Key takeaways
- Delivered 15% reported revenue growth (11% organic) with $194 million in Q1 sales, driven by broad-based strength across customer segments and geographies.
- Adjusted operating margin expanded by 160 basis points, aided by disciplined cost management and the strategic sale of the low-margin Polymem business.
- Maintained full-year organic growth guidance of 9% to 13%, while slightly lowering reported revenue guidance to reflect the Polymem divestiture, which improved margin expectations.
- Growth led by Analytics (+50%+), Services (+30%+), and double-digit Consumables; strong capital equipment demand supported by easier comps and a healthy order funnel.
- Advanced strategic priorities with the launch of a transformation office targeting at least one point of annualized margin improvement by end of 2027 and expanded partnerships in China, which delivered the best quarterly revenue in over two years.
Q3 2025
Oct 29, 2025
Repligen Corporation reported strong Q3 2025 results with 18% organic growth driven by robust performance across all franchises and geographies, alongside a positive momentum in both biopharma and CDMO markets.
Key takeaways
- Q3 organic revenue growth reached 18%, with all franchises achieving double-digit growth and analytics leading at over 50%.
- Total company orders grew sequentially for six consecutive quarters, with year-over-year order growth exceeding 20%.
- The company raised its organic growth guidance midpoint for 2025, highlighting broad strength across its portfolio.
- A partnership with Novasign aims to enhance digital twin capabilities in manufacturing processes, marking a significant step in their digitization strategy.
- Service revenue represented 5% of consolidated revenue and shows potential for future growth through expanded offerings.
Q2 2025
Aug 2, 2025
Repligen Corporation delivered an outstanding Q2 2025 with 17% organic non-COVID growth, marking the highest growth rate since 2022, driven by robust performance across its biopharma and consumables segments.
Key takeaways
- Biopharma revenue grew 20% year-over-year, with orders increasing over 20%, fueled by wins at large pharma clients.
- Consumable revenue achieved a record high, surpassing 20% growth, while capital equipment revenue returned to growth in the high teens.
- Orders consistently outpaced revenue for the eighth consecutive quarter, reflecting strong demand across diversified product offerings, particularly in filtration.
- The company raised its revenue guidance for 2025 to a range of $715 million to $735 million, highlighting confidence in continued momentum amid macroeconomic challenges.